285: CRISPR history, biotech struggles, & a big week for deals
The Readout Loud
00:00
Discussion on Atlas's performance and acquisitions in the obesity space
A discussion on the performance of Atlas throughout the year, including the acquisition of their obesity-focused companies by other organizations. They also highlight the successful acquisition of Nimbus's TIC2 program by TICADA and Versa. The chapter concludes with gratitude for the guest and contact information for feedback.
Transcript
Play full episode
